3451. Protelos Article-20 procedure: CHMP scientific conclusions and PRAC assessment report 3452. Revlimid-H-C-PSUSA-00001838-201612 3453. Stivarga-H-C-PSUV-0004 3454. PecFent-H-C-PSUSA-00001369-201704 3455. Karvea-H-C-PSUSA-00001782-201506 3456. Leganto-H-C-PSUSA-00002667-201702 3457. Bydureon-H-C-2020-PSUV-0024 3458. Revlimid-H-C-PSUSA-1838-201512 3459. Ioa-H-C-2068-PSU-05 3460. Pegasys-H-C-395-PSUV-0072 3461. Victrelis-H-C-2332-PSUV-0024 3462. Exjade-H-C-PSUSA-00000939-201510 3463. Thymanax-H-C-916-PSUV-0021 3464. Adcirca-H-C-PSUSA-00002841-201410 3465. Evoltra-H-C-613-PSUV-0044: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation 3466. Xarelto-H-C-PSUSA-00002653-201709 3467. Zydelig-H-C-10303-201701 3468. Picato-H-C-PSUSA-00010035-201507 3469. Cubicin-H-C-PSUSA-00000931-201709 3470. Brimica Genuair-H-C-PSUSA-10307-201605 3471. Zometa-H-C-PSUSA-00003149-201608 3472. IntronA -H-C-PSUSA-00001758-201609: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation 3473. Xaluprine-H-C-2022-PSUV-08 3474. Remicade-H-C-240-PSUV-0180 3475. Betmiga-H-C-2388-PSUV-0015 3476. Keppra-H-C-PSUSA-1846-201511 3477. Elaprase-H-C-700-PSUV-0047 3478. Exviera-H-C-PSUSA-00010363-201507 3479. Telmisartan Teva Pharma-H-C-2511-A31-0006 : Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC ... 3480. Zevalin-H-C-PSUSA-1704-201704 - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation